Automate Your Wheel Strategy on SNY
With Tiblio's Option Bot, you can configure your own wheel strategy including SNY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNY
- Rev/Share 17.4767
- Book/Share 28.4784
- PB 1.4864
- Debt/Equity 0.3183
- CurrentRatio 1.2739
- ROIC 0.0666
- MktCap 103757214307.3104
- FreeCF/Share 0.8481
- PFCF 49.5734
- PE 11.4022
- Debt/Assets 0.1783
- DivYield 0.0453
- ROE 0.1239
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SNY | Morgan Stanley | Equal Weight | Overweight | -- | $58 | Sept. 8, 2025 |
| Upgrade | SNY | Deutsche Bank | Hold | Buy | -- | -- | Sept. 2, 2025 |
| Upgrade | SNY | JP Morgan | Neutral | Overweight | -- | -- | Aug. 8, 2025 |
| Initiation | SNY | Exane BNP Paribas | -- | Outperform | -- | $65 | April 15, 2025 |
| Initiation | SNY | Goldman | -- | Neutral | -- | $65 | March 21, 2025 |
| Upgrade | SNY | Deutsche Bank | Sell | Hold | -- | -- | Jan. 30, 2025 |
News
Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
Published: May 14, 2025 by: PRNewsWire
Sentiment: Neutral
MORRISTOWN, N.J. and CAMBRIDGE, Mass.
Read More
Sanofi: Investing in prevention builds Europe's health and competitiveness
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARSAW, Poland, May 06, 2025 (GLOBE NEWSWIRE) -- As the Polish Presidency of the EU Council enters its final stage health policy remains central to Europe's strategic agenda. At the European Economic Congress in Katowice, discussions reflected both the Presidency's efforts to strengthen healthcare resilience and drive digital transformation, and a broader consensus that prevention, innovation, and life science leadership must be at the core of Europe's long-term strategy. Sanofi's experts highlighted the pivotal role of immunization, respiratory health, and sustainable innovation in building a healthier and competitive Europe.
Read More
Press Release: Annual General Meeting of April 30, 2025
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025 Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders' Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa.
Read More
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy.
Read More
Sanofi (SNY) Q1 2025 Earnings Call Transcript
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Sanofi (NASDAQ:SNY ) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ET Company Participants Thomas Kudsk Larsen - Head, Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Officer Houman Ashrafian - Executive Vice President, Head of Research & Development Thomas Triomphe - Executive Vice President, Vaccines Brian Foard - Executive Vice President, Head of Specialty Care Conference Call Participants Richard Vosser - JPMorgan Luisa Hector - Berenberg Colleen Garvey - Guggenheim Ben Jackson - Jefferies Peter Verdult - BNP Exane Jo Walton - UBS Graham …
Read More
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
Published: April 18, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Read More
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Published: April 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved Paris and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents …
Read More
Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on lunsekimig and itepekimab studies.
Read More
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Published: April 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosis Tolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MS Tolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026 Paris, …
Read More
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA bestows an orphan drug designation to Sanofi's rilzabrutinib for treating warm autoimmune hemolytic anemia and IgG4-related disease.
Read More
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune thrombocytopenia Paris, April 3, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton's tyrosine kinase (BTK) inhibitor, for two rare diseases, warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD).
Read More
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Published: April 01, 2025 by: CNBC Television
Sentiment: Negative
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.
Read More
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.
Read More
US FDA approves Sanofi's bleeding disorder therapy
Published: March 28, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents blood from clotting properly, the regulator said on Friday.
Read More
Sanofi's Chlamydia Vaccine Candidate Gets FDA's Fast Track Tag
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA bestows a fast-track designation to SNY's mRNA vaccine candidate for the prevention of chlamydia infection.
Read More
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Positive
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in multiple sclerosis.
Read More
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to pregnancy complications or infertility A phase 1/2 clinical study evaluating the immunogenicity and safety of the vaccine candidate is due to start in coming days Paris, March 26, 2025. The US Food and Drug Administration has granted fast track designation to Sanofi's mRNA vaccine candidate for the prevention of chlamydia infection.
Read More
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activity Tolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MS Tolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MS Paris, March 25, 2025. The US Food and Drug …
Read More
Press Release: Availability of the Q1 2025 Aide mémoire
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.
Read More
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Through the Dren Bio deal, SNY intends to expand its immunology pipeline and establish itself as a leading immunology company.
Read More
Sanofi to acquire Dren Bio's immunology unit
Published: March 20, 2025 by: Reuters
Sentiment: Positive
Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.
Read More
Press Release: Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front Paris, March 20, 2025. Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies.
Read More
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
Published: March 14, 2025 by: PRNewsWire
Sentiment: Neutral
BRIDGEWATER, N.J. , March 14, 2025 /PRNewswire/ -- Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US.
Read More
Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue?
Published: March 12, 2025 by: Benzinga
Sentiment: Positive
Sanofi NV SNY has been flexing its biotech muscles, and investors are taking notice. The stock is firmly in bullish territory, recently forming a Golden Cross , a classic technical signal that often precedes further gains.
Read More
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from the IMROZ phase 3 study that demonstrated Sarclisa in combination with VRd significantly improved progression-free survival, compared to VRd alone in transplant-ineligible newly diagnosed multiple myeloma Paris, February 25, 2025. The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) based on data from the IMROZ phase 3 …
Read More
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025 . Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed the share purchase agreement in relation to the sale of a 50% controlling stake in Opella to CD&R.
Read More
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
Published: February 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Read More
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d'Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF).
Read More
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient efficacy in preventing invasive E.
Read More
About Sanofi (SNY)
- IPO Date 2002-07-01
- Website https://www.sanofi.com
- Industry Drug Manufacturers - General
- CEO Paul Hudson
- Employees 82878